Pharma’s Pipeline Getting Fuller; Parexel Finds 8.2% Jump In Trial Starts
While pharmaceutical companies have been bemoaning the dearth of new drugs coming on the market, things may be looking up
You may also be interested in...
While India now ranks among the top 10 countries conducting FDA-regulated clinical trials, it has yet to see a major influx of trial work
Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization
Oncologics led the pharmaceutical industry's investigational new drug application submissions over other drug classes in fiscal year 2005, according to an analysis by Parexel